U.S., Oct. 4 -- ClinicalTrials.gov registry received information related to the study (NCT07205198) titled 'A Clinical Trial of SIBP-A10 Injection in the Treatment of Advanced Malignant Tumor Subjects.' on Sept. 24.
Brief Summary: To evaluate the safety, tolerability of SIBP-A10 and determine the maximum tolerable dose (MTD) and phase II recommended dose (RP2D).
Study Start Date: Sept. 30
Study Type: INTERVENTIONAL
Condition:
Advanced Tumors
Intervention:
DRUG: SIBP-A10
SIBP-A10 injection. Strength: 0.5, 1.5, 3, 5, 7, 10 and 15 mg/kg. Intravenous infusion administration, with a treatment cycle of every 21 days, administered once on the first day of each cycle. The dose escalation stage,0.5 mg/kg group was subjected to accelerated ti...